UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 117

Sortiert nach

The Classical Complement Pathway Mediates Microglia-Dependent Remodeling of Spinal Motor Circuits during Development and in SMA

Cell reports (Cambridge), 2019-12, Vol.29 (10), p.3087-3100.e7

2019

Volltextzugriff (PDF)

Anti-JC virus antibodies: Implications for PML Risk Stratification

Annals of neurology, 2010-09, Vol.68 (3), p.295-303

2010

Volltextzugriff (PDF)

C1q and the classical complement cascade in geographic atrophy secondary to age-related macular degeneration

International journal of retina and vitreous, 2022-11, Vol.8 (1), p.1-79, Article 79

2022

Volltextzugriff (PDF)

C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy

Acta neuropathologica communications, 2016-03, Vol.4 (22), p.23-23, Article 23

2016

Volltextzugriff (PDF)

Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS

PloS one, 2012-07, Vol.7 (7), p.e40443-e40443

2012

Volltextzugriff (PDF)

Systems-based analyses of brain regions functionally impacted in Parkinson's disease reveals underlying causal mechanisms

PloS one, 2014-08, Vol.9 (8), p.e102909-e102909

2014

Volltextzugriff (PDF)

Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease

PloS one, 2013-08, Vol.8 (8), p.e71634-e71634

2013

Volltextzugriff (PDF)

Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin

The American journal of gastroenterology, 2003-11, Vol.98 (11), p.2372-2382

2003

Volltextzugriff (PDF)

Epitope and Isotype Specificities of Antibodies to β-Amyloid Peptide for Protection against Alzheimer's Disease-like Neuropathology

Proceedings of the National Academy of Sciences - PNAS, 2003-02, Vol.100 (4), p.2023-2028

2003

Volltextzugriff (PDF)

Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease

Ophthalmology science (Online), 2023-06, Vol.3 (2), p.100290, Article 100290

2023

Volltextzugriff (PDF)

Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: Prime side chromane-containing inhibitors

Bioorganic & medicinal chemistry letters, 2013-08, Vol.23 (16), p.4674-4679

2013

Volltextzugriff (PDF)

Anti-Mcam Monoclonal Antibody PRX003 Inhibits the Unique Migratory Potential of Pathogenic IL-17–Producing T Cells

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB190-AB190

2016

Volltextzugriff (PDF)

Design and synthesis of a novel, orally active, brain penetrant, tri-substituted thiophene based JNK inhibitor

Bioorganic & medicinal chemistry letters, 2011-03, Vol.21 (6), p.1838-1843

2011

Volltextzugriff (PDF)

Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri ®) with endogenous IgG4

Journal of pharmaceutical and biomedical analysis, 2011-04, Vol.55 (1), p.168-175

2011

Volltextzugriff (PDF)

Discovery of (R)‑4-Cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro‑1H‑pyrazolo[4,3‑c]quinoline (ELND006) and (R)‑4-Cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro‑2H‑pyrazolo[4,3‑c]quinoline (ELND007): Metabolically Stable γ‑Secretase Inhibitors that Selectively Inhibit the Production of Amyloid‑β over Notch

Journal of medicinal chemistry, 2013-07, Vol.56 (13), p.5261-5274

2013

Volltextzugriff (PDF)

Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration

Bioorganic & medicinal chemistry letters, 2011-09, Vol.21 (18), p.5521-5527

2011

Volltextzugriff (PDF)

PEG conjugates of potent α4 integrin inhibitors, maintaining sustained levels and bioactivity in vivo, following subcutaneous administration

Bioorganic & medicinal chemistry letters, 2013-07, Vol.23 (14), p.4117-4119

2013

Volltextzugriff (PDF)

Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration

Bioorganic & medicinal chemistry letters, 2011-01, Vol.21 (1), p.315-319

2011

Volltextzugriff (PDF)

Orally available and efficacious α4β1/α4β7 integrin inhibitors

Bioorganic & medicinal chemistry letters, 2013-08, Vol.23 (15), p.4370-4373

2013

Volltextzugriff (PDF)

Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK

Bioorganic & medicinal chemistry letters, 2010-12, Vol.20 (24), p.7303-7307

2010

Volltextzugriff (PDF)

Effects of an alpha-4 integrin inhibitor on restenosis in a new porcine model combining endothelial denudation and stent placement

PloS one, 2010-12, Vol.5 (12), p.e14314-e14314

2010

Volltextzugriff (PDF)

Highly selective c-Jun N-terminal kinase (JNK) 3 inhibitors with in vitro CNS-like pharmacokinetic properties II. Central core replacement

Bioorganic & medicinal chemistry letters, 2011-06, Vol.21 (12), p.3726-3729

2011

Volltextzugriff (PDF)

Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: Structure–activity relationship of P2′ substituents

Bioorganic & medicinal chemistry letters, 2010-08, Vol.20 (16), p.4789-4794

2010

Volltextzugriff (PDF)

1 – 25 von 117

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(116)
Mit Volltextzugriff
(108)

Publikationsform

Sprache

Englisch
(117)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Animals
(39)
Humans
(38)
Life Sciences & Biomedicine
(36)
Mice
(26)
Biological And Medical Sciences
(24)
Chemistry
(16)
Pharmacology & Pharmacy
(16)
Medical Sciences
(15)
Chemistry, Medicinal
(14)
Physical Sciences
(13)
Structure-Activity Relationship
(13)
Alzheimer's Disease
(12)
Chemistry, Organic
(12)
Disease Models, Animal
(10)
Fundamental And Applied Biological Sciences. Psychology
(10)
Multidisciplinary Sciences
(10)
Pharmacology. Drug Treatments
(10)
Science & Technology - Other Topics
(10)
Proteins
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Classical Complement Pathway Mediates Microglia-Dependent Remodeling of Spinal Motor Circuits during Development and in SMA

Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease

Anti-JC virus antibodies: Implications for PML Risk Stratification

Targeting the Intrinsically Disordered Structural Ensemble of [alpha]-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson's Disease

C1q and the classical complement cascade in geographic atrophy secondary to age-related macular degeneration

C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy

Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS

Systems-based analyses of brain regions functionally impacted in Parkinson's disease reveals underlying causal mechanisms

Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease

Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin

Epitope and Isotype Specificities of Antibodies to β-Amyloid Peptide for Protection against Alzheimer's Disease-like Neuropathology

Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease

Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: Prime side chromane-containing inhibitors

Anti-Mcam Monoclonal Antibody PRX003 Inhibits the Unique Migratory Potential of Pathogenic IL-17–Producing T Cells

Design and synthesis of a novel, orally active, brain penetrant, tri-substituted thiophene based JNK inhibitor

Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri ®) with endogenous IgG4

Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration

PEG conjugates of potent α4 integrin inhibitors, maintaining sustained levels and bioactivity in vivo, following subcutaneous administration

Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration

Orally available and efficacious α4β1/α4β7 integrin inhibitors

Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK

Effects of an alpha-4 integrin inhibitor on restenosis in a new porcine model combining endothelial denudation and stent placement

Highly selective c-Jun N-terminal kinase (JNK) 3 inhibitors with in vitro CNS-like pharmacokinetic properties II. Central core replacement

Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: Structure–activity relationship of P2′ substituents

Suchergebnisse filtern